{"entity":{"type":"insider","cik":"0001636701","url":"/insider/0001636701","json_url":"/insider/0001636701.json","name":"Oren Dan","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":40,"n_filings":20,"first":"2018-04-04","last":"2022-11-14","span_basis":"filed_date"},"name_variants":[{"name":"Oren Dan","source":"filing","n_filings":20,"first_seen":"2018-04-04","last_seen":"2022-11-14"}],"transactions":[{"id":6150946,"accession":"0001104659-22-117847","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-22-117847","line_url":"/filing/0001104659-22-117847#line-1","is_derivative":false,"issuer_cik":"0001635088","issuer_name":"Roivant Sciences Ltd.","issuer_ticker":"ROIV","issuer_name_source":null,"issuer_url":"/issuer/0001635088","owner_cik":null,"owner_name":"Oren Dan; Dexxon Holdings Ltd.; Dexcel Pharma Technologies Ltd.","owner_display_name":"Oren Dan","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4000000.0,"shares_display":"4,000,000","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":20000000.0,"total_display":"20,000,000.00","total_whole":"20,000,000","shares_owned_after":102849443.0,"shares_owned_after_display":"102,849,443","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-11-10","filed_date":"2022-11-14","scope":"insider"},{"id":6418451,"accession":"0001104659-22-049930","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-22-049930","line_url":"/filing/0001104659-22-049930#line-2","is_derivative":false,"issuer_cik":"0001635088","issuer_name":"Roivant Sciences Ltd.","issuer_ticker":"ROIV","issuer_name_source":null,"issuer_url":"/issuer/0001635088","owner_cik":null,"owner_name":"Dexcel Pharma Technologies Ltd.; Dexxon Holdings Ltd.; Oren Dan","owner_display_name":"Dexcel Pharma Technologies Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":8600.0,"shares_display":"8,600","price_per_share":3.9111,"price_display":"3.91","price_state":"stated","total_value":33635.46,"total_display":"33,635.46","total_whole":"33,635","shares_owned_after":98849443.0,"shares_owned_after_display":"98,849,443","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-25","filed_date":"2022-04-26","scope":"insider"},{"id":6418448,"accession":"0001104659-22-049930","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-22-049930","line_url":"/filing/0001104659-22-049930#line-1","is_derivative":false,"issuer_cik":"0001635088","issuer_name":"Roivant Sciences Ltd.","issuer_ticker":"ROIV","issuer_name_source":null,"issuer_url":"/issuer/0001635088","owner_cik":null,"owner_name":"Dexcel Pharma Technologies Ltd.; Dexxon Holdings Ltd.; Oren Dan","owner_display_name":"Dexcel Pharma Technologies Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":31685.0,"shares_display":"31,685","price_per_share":3.8289,"price_display":"3.83","price_state":"stated","total_value":121318.6965,"total_display":"121,318.70","total_whole":"121,319","shares_owned_after":98840843.0,"shares_owned_after_display":"98,840,843","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-04-22","filed_date":"2022-04-26","scope":"insider"},{"id":4409932,"accession":"0001104659-21-076488","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-21-076488","line_url":"/filing/0001104659-21-076488#line-2","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":null,"owner_name":"Dexcel Pharma Technologies Ltd.; Oren Dan","owner_display_name":"Dexcel Pharma Technologies Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":857506.0,"shares_display":"857,506","price_per_share":2.2534,"price_display":"2.25","price_state":"stated","total_value":1932304.0204,"total_display":"1,932,304.02","total_whole":"1,932,304","shares_owned_after":3637314.0,"shares_owned_after_display":"3,637,314","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-03","filed_date":"2021-06-03","scope":"insider"},{"id":4409930,"accession":"0001104659-21-076488","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-21-076488","line_url":"/filing/0001104659-21-076488#line-1","is_derivative":false,"issuer_cik":"0001006281","issuer_name":"Protalix BioTherapeutics, Inc.","issuer_ticker":"PLX","issuer_name_source":null,"issuer_url":"/issuer/0001006281","owner_cik":null,"owner_name":"Dexcel Pharma Technologies Ltd.; Oren Dan","owner_display_name":"Dexcel Pharma Technologies Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":61211.0,"shares_display":"61,211","price_per_share":2.5576,"price_display":"2.56","price_state":"stated","total_value":156553.2536,"total_display":"156,553.25","total_whole":"156,553","shares_owned_after":4494820.0,"shares_owned_after_display":"4,494,820","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-02","filed_date":"2021-06-03","scope":"insider"},{"id":3243550,"accession":"0001104659-20-010828","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001104659-20-010828","line_url":"/filing/0001104659-20-010828#line-3","is_derivative":false,"issuer_cik":"0001636701","issuer_name":"Intec Pharma Ltd.","issuer_ticker":"NTEC","issuer_name_source":null,"issuer_url":"/issuer/0001636701","owner_cik":null,"owner_name":"Oren Dan; Dexcel Pharma Technologies Ltd.","owner_display_name":"Oren Dan","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":110000.0,"shares_display":"110,000","price_per_share":0.29,"price_display":"0.29","price_state":"stated","total_value":31900.0,"total_display":"31,900.00","total_whole":"31,900","shares_owned_after":4234897.0,"shares_owned_after_display":"4,234,897","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-02-04","filed_date":"2020-02-04","scope":"insider"},{"id":3243546,"accession":"0001104659-20-010828","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001104659-20-010828","line_url":"/filing/0001104659-20-010828#line-2","is_derivative":false,"issuer_cik":"0001636701","issuer_name":"Intec Pharma Ltd.","issuer_ticker":"NTEC","issuer_name_source":null,"issuer_url":"/issuer/0001636701","owner_cik":null,"owner_name":"Oren Dan; Dexcel Pharma Technologies Ltd.","owner_display_name":"Oren Dan","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":80000.0,"shares_display":"80,000","price_per_share":0.318,"price_display":"0.32","price_state":"stated","total_value":25440.0,"total_display":"25,440.00","total_whole":"25,440","shares_owned_after":4344897.0,"shares_owned_after_display":"4,344,897","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-02-03","filed_date":"2020-02-04","scope":"insider"},{"id":3243538,"accession":"0001104659-20-010828","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001104659-20-010828","line_url":"/filing/0001104659-20-010828#line-1","is_derivative":false,"issuer_cik":"0001636701","issuer_name":"Intec Pharma Ltd.","issuer_ticker":"NTEC","issuer_name_source":null,"issuer_url":"/issuer/0001636701","owner_cik":null,"owner_name":"Oren Dan; Dexcel Pharma Technologies Ltd.","owner_display_name":"Oren Dan","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Ordinary Shares","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":725951.0,"shares_display":"725,951","price_per_share":0.309,"price_display":"0.31","price_state":"stated","total_value":224318.859,"total_display":"224,318.86","total_whole":"224,319","shares_owned_after":4424897.0,"shares_owned_after_display":"4,424,897","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-01-31","filed_date":"2020-02-04","scope":"insider"},{"id":8220498,"accession":"0001144204-19-031542","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-19-031542","line_url":"/filing/0001144204-19-031542#line-3","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Dexcel Pharma Technologies Ltd.; Oren Dan; Dexxon Holdings Ltd.","owner_display_name":"Dexcel Pharma Technologies Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4957.0,"shares_display":"4,957","price_per_share":8.1693,"price_display":"8.17","price_state":"stated","total_value":40495.2201,"total_display":"40,495.22","total_whole":"40,495","shares_owned_after":22860013.0,"shares_owned_after_display":"22,860,013","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-19","filed_date":"2019-06-19","scope":"insider"},{"id":8220493,"accession":"0001144204-19-031542","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-19-031542","line_url":"/filing/0001144204-19-031542#line-2","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Dexcel Pharma Technologies Ltd.; Oren Dan; Dexxon Holdings Ltd.","owner_display_name":"Dexcel Pharma Technologies Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6706.0,"shares_display":"6,706","price_per_share":8.2107,"price_display":"8.21","price_state":"stated","total_value":55060.9542,"total_display":"55,060.95","total_whole":"55,061","shares_owned_after":22855056.0,"shares_owned_after_display":"22,855,056","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-18","filed_date":"2019-06-19","scope":"insider"},{"id":8220488,"accession":"0001144204-19-031542","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-19-031542","line_url":"/filing/0001144204-19-031542#line-1","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Dexcel Pharma Technologies Ltd.; Oren Dan; Dexxon Holdings Ltd.","owner_display_name":"Dexcel Pharma Technologies Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares, $0.000037453 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6541.0,"shares_display":"6,541","price_per_share":8.5346,"price_display":"8.53","price_state":"stated","total_value":55824.8186,"total_display":"55,824.82","total_whole":"55,825","shares_owned_after":22848350.0,"shares_owned_after_display":"22,848,350","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-17","filed_date":"2019-06-19","scope":"insider"},{"id":8367516,"accession":"0001144204-19-031054","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-19-031054","line_url":"/filing/0001144204-19-031054#line-3","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Dexcel Pharma Technologies Ltd.; Dexxon Holdings Ltd.; Oren Dan","owner_display_name":"Dexcel Pharma Technologies Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7144.0,"shares_display":"7,144","price_per_share":7.9107,"price_display":"7.91","price_state":"stated","total_value":56514.0408,"total_display":"56,514.04","total_whole":"56,514","shares_owned_after":22841809.0,"shares_owned_after_display":"22,841,809","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-14","filed_date":"2019-06-14","scope":"insider"},{"id":8367513,"accession":"0001144204-19-031054","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-19-031054","line_url":"/filing/0001144204-19-031054#line-2","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Dexcel Pharma Technologies Ltd.; Dexxon Holdings Ltd.; Oren Dan","owner_display_name":"Dexcel Pharma Technologies Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7367.0,"shares_display":"7,367","price_per_share":7.9466,"price_display":"7.95","price_state":"stated","total_value":58542.6022,"total_display":"58,542.60","total_whole":"58,543","shares_owned_after":22834665.0,"shares_owned_after_display":"22,834,665","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-13","filed_date":"2019-06-14","scope":"insider"},{"id":8367509,"accession":"0001144204-19-031054","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-19-031054","line_url":"/filing/0001144204-19-031054#line-1","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Dexcel Pharma Technologies Ltd.; Dexxon Holdings Ltd.; Oren Dan","owner_display_name":"Dexcel Pharma Technologies Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares, $0.000037453 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7500.0,"shares_display":"7,500","price_per_share":8.2992,"price_display":"8.30","price_state":"stated","total_value":62244.0,"total_display":"62,244.00","total_whole":"62,244","shares_owned_after":22827298.0,"shares_owned_after_display":"22,827,298","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-12","filed_date":"2019-06-14","scope":"insider"},{"id":8220412,"accession":"0001144204-19-030612","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-19-030612","line_url":"/filing/0001144204-19-030612#line-3","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Dexxon Holdings Ltd.; Oren Dan; Dexcel Pharma Technologies Ltd.","owner_display_name":"Dexxon Holdings Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7189.0,"shares_display":"7,189","price_per_share":8.5817,"price_display":"8.58","price_state":"stated","total_value":61693.8413,"total_display":"61,693.84","total_whole":"61,694","shares_owned_after":22819798.0,"shares_owned_after_display":"22,819,798","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-11","filed_date":"2019-06-11","scope":"insider"},{"id":8220408,"accession":"0001144204-19-030612","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-19-030612","line_url":"/filing/0001144204-19-030612#line-2","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Dexxon Holdings Ltd.; Oren Dan; Dexcel Pharma Technologies Ltd.","owner_display_name":"Dexxon Holdings Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7500.0,"shares_display":"7,500","price_per_share":8.3459,"price_display":"8.35","price_state":"stated","total_value":62594.25,"total_display":"62,594.25","total_whole":"62,594","shares_owned_after":22812609.0,"shares_owned_after_display":"22,812,609","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-10","filed_date":"2019-06-11","scope":"insider"},{"id":8220403,"accession":"0001144204-19-030612","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-19-030612","line_url":"/filing/0001144204-19-030612#line-1","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Dexxon Holdings Ltd.; Oren Dan; Dexcel Pharma Technologies Ltd.","owner_display_name":"Dexxon Holdings Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares, $0.000037453 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6649.0,"shares_display":"6,649","price_per_share":7.965,"price_display":"7.96","price_state":"stated","total_value":52959.285,"total_display":"52,959.28","total_whole":"52,959","shares_owned_after":22805109.0,"shares_owned_after_display":"22,805,109","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-07","filed_date":"2019-06-11","scope":"insider"},{"id":8060248,"accession":"0001144204-19-030138","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-19-030138","line_url":"/filing/0001144204-19-030138#line-3","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Oren Dan; Dexcel Pharma Technologies Ltd.; Dexxon Holdings Ltd.","owner_display_name":"Oren Dan","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7082.0,"shares_display":"7,082","price_per_share":7.9951,"price_display":"8.00","price_state":"stated","total_value":56621.2982,"total_display":"56,621.30","total_whole":"56,621","shares_owned_after":22798460.0,"shares_owned_after_display":"22,798,460","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-06","filed_date":"2019-06-06","scope":"insider"},{"id":8060239,"accession":"0001144204-19-030138","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-19-030138","line_url":"/filing/0001144204-19-030138#line-2","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Oren Dan; Dexcel Pharma Technologies Ltd.; Dexxon Holdings Ltd.","owner_display_name":"Oren Dan","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6540.0,"shares_display":"6,540","price_per_share":8.015,"price_display":"8.02","price_state":"stated","total_value":52418.1,"total_display":"52,418.10","total_whole":"52,418","shares_owned_after":22791378.0,"shares_owned_after_display":"22,791,378","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-05","filed_date":"2019-06-06","scope":"insider"},{"id":8060235,"accession":"0001144204-19-030138","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-19-030138","line_url":"/filing/0001144204-19-030138#line-1","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Oren Dan; Dexcel Pharma Technologies Ltd.; Dexxon Holdings Ltd.","owner_display_name":"Oren Dan","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares, $0.000037453 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7500.0,"shares_display":"7,500","price_per_share":7.5881,"price_display":"7.59","price_state":"stated","total_value":56910.75,"total_display":"56,910.75","total_whole":"56,911","shares_owned_after":22784838.0,"shares_owned_after_display":"22,784,838","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-04","filed_date":"2019-06-06","scope":"insider"},{"id":7974487,"accession":"0001144204-19-030140","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-19-030140","line_url":"/filing/0001144204-19-030140#line-1","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Dexcel Pharma Technologies Ltd.; Dexxon Holdings Ltd.; Oren Dan","owner_display_name":"Dexcel Pharma Technologies Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares, $0.000017727 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2424242.0,"shares_display":"2,424,242","price_per_share":8.25,"price_display":"8.25","price_state":"stated","total_value":19999996.5,"total_display":"19,999,996.50","total_whole":"19,999,997","shares_owned_after":40765599.0,"shares_owned_after_display":"40,765,599","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-04","filed_date":"2019-06-06","scope":"insider"},{"id":8367497,"accession":"0001144204-19-029540","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001144204-19-029540","line_url":"/filing/0001144204-19-029540#line-4","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Dexcel Pharma Technologies Ltd.; Dexxon Holdings Ltd.; Oren Dan","owner_display_name":"Dexcel Pharma Technologies Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5424.0,"shares_display":"5,424","price_per_share":7.7092,"price_display":"7.71","price_state":"stated","total_value":41814.7008,"total_display":"41,814.70","total_whole":"41,815","shares_owned_after":22777338.0,"shares_owned_after_display":"22,777,338","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-03","filed_date":"2019-06-03","scope":"insider"},{"id":8367491,"accession":"0001144204-19-029540","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-19-029540","line_url":"/filing/0001144204-19-029540#line-3","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Dexcel Pharma Technologies Ltd.; Dexxon Holdings Ltd.; Oren Dan","owner_display_name":"Dexcel Pharma Technologies Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5071.0,"shares_display":"5,071","price_per_share":7.6991,"price_display":"7.70","price_state":"stated","total_value":39042.1361,"total_display":"39,042.14","total_whole":"39,042","shares_owned_after":22771914.0,"shares_owned_after_display":"22,771,914","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-31","filed_date":"2019-06-03","scope":"insider"},{"id":8367487,"accession":"0001144204-19-029540","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-19-029540","line_url":"/filing/0001144204-19-029540","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Dexcel Pharma Technologies Ltd.; Dexxon Holdings Ltd.; Oren Dan","owner_display_name":"Dexcel Pharma Technologies Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares, $0.000037453 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7251.0,"shares_display":"7,251","price_per_share":8.011242945800578,"price_display":"8.01","price_state":"stated","total_value":58089.5226,"total_display":"58,089.52","total_whole":"58,090","shares_owned_after":22766543.0,"shares_owned_after_display":"22,766,543","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-30","filed_date":"2019-06-03","scope":"insider","n_lines":2},{"id":8133027,"accession":"0001144204-19-028688","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001144204-19-028688","line_url":"/filing/0001144204-19-028688#line-3","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Dexxon Holdings Ltd.; Dexcel Pharma Technologies Ltd.; Oren Dan","owner_display_name":"Dexxon Holdings Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6882.0,"shares_display":"6,882","price_per_share":7.5535,"price_display":"7.55","price_state":"stated","total_value":51983.187,"total_display":"51,983.19","total_whole":"51,983","shares_owned_after":22759592.0,"shares_owned_after_display":"22,759,592","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-29","filed_date":"2019-05-29","scope":"insider"},{"id":8133024,"accession":"0001144204-19-028688","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-19-028688","line_url":"/filing/0001144204-19-028688#line-2","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Dexxon Holdings Ltd.; Dexcel Pharma Technologies Ltd.; Oren Dan","owner_display_name":"Dexxon Holdings Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3807.0,"shares_display":"3,807","price_per_share":7.6818,"price_display":"7.68","price_state":"stated","total_value":29244.6126,"total_display":"29,244.61","total_whole":"29,245","shares_owned_after":22752710.0,"shares_owned_after_display":"22,752,710","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-28","filed_date":"2019-05-29","scope":"insider"},{"id":8133022,"accession":"0001144204-19-028688","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-19-028688","line_url":"/filing/0001144204-19-028688#line-1","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Dexxon Holdings Ltd.; Dexcel Pharma Technologies Ltd.; Oren Dan","owner_display_name":"Dexxon Holdings Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares, $0.000037453 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3796.0,"shares_display":"3,796","price_per_share":7.7011,"price_display":"7.70","price_state":"stated","total_value":29233.3756,"total_display":"29,233.38","total_whole":"29,233","shares_owned_after":22748903.0,"shares_owned_after_display":"22,748,903","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-24","filed_date":"2019-05-29","scope":"insider"},{"id":8096674,"accession":"0001144204-19-028456","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-19-028456","line_url":"/filing/0001144204-19-028456#line-2","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Oren Dan; Dexxon Holdings Ltd.; Dexcel Pharma Technologies Ltd.","owner_display_name":"Oren Dan","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4802.0,"shares_display":"4,802","price_per_share":7.7576,"price_display":"7.76","price_state":"stated","total_value":37251.9952,"total_display":"37,252.00","total_whole":"37,252","shares_owned_after":22745107.0,"shares_owned_after_display":"22,745,107","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-23","filed_date":"2019-05-28","scope":"insider"},{"id":8096671,"accession":"0001144204-19-028456","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-19-028456","line_url":"/filing/0001144204-19-028456#line-1","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Oren Dan; Dexxon Holdings Ltd.; Dexcel Pharma Technologies Ltd.","owner_display_name":"Oren Dan","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares, $0.000037453 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5033.0,"shares_display":"5,033","price_per_share":8.0584,"price_display":"8.06","price_state":"stated","total_value":40557.9272,"total_display":"40,557.93","total_whole":"40,558","shares_owned_after":22740305.0,"shares_owned_after_display":"22,740,305","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-22","filed_date":"2019-05-28","scope":"insider"},{"id":7786070,"accession":"0001144204-19-027995","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-19-027995","line_url":"/filing/0001144204-19-027995#line-1","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Dexcel Pharma Technologies Ltd.; Oren Dan; Dexxon Holdings Ltd.","owner_display_name":"Dexcel Pharma Technologies Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares, $0.000037453 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":9995.0,"shares_display":"9,995","price_per_share":8.5151,"price_display":"8.52","price_state":"stated","total_value":85108.4245,"total_display":"85,108.42","total_whole":"85,108","shares_owned_after":22735272.0,"shares_owned_after_display":"22,735,272","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-21","filed_date":"2019-05-23","scope":"insider"},{"id":8060216,"accession":"0001144204-19-027731","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-19-027731","line_url":"/filing/0001144204-19-027731","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Dexcel Pharma Technologies Ltd.; Dexxon Holdings Ltd.; Oren Dan","owner_display_name":"Dexcel Pharma Technologies Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares, $0.000037453 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000.0,"shares_display":"10,000","price_per_share":8.0524831,"price_display":"8.05","price_state":"stated","total_value":80524.831,"total_display":"80,524.83","total_whole":"80,525","shares_owned_after":22723562.0,"shares_owned_after_display":"22,723,562","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-20","filed_date":"2019-05-22","scope":"insider","n_lines":2},{"id":8156911,"accession":"0001144204-19-027306","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001144204-19-027306","line_url":"/filing/0001144204-19-027306#line-2","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Dexcel Pharma Technologies Ltd.; Dexxon Holdings Ltd.; Oren Dan","owner_display_name":"Dexcel Pharma Technologies Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6200.0,"shares_display":"6,200","price_per_share":7.3615,"price_display":"7.36","price_state":"stated","total_value":45641.3,"total_display":"45,641.30","total_whole":"45,641","shares_owned_after":22715277.0,"shares_owned_after_display":"22,715,277","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-17","filed_date":"2019-05-20","scope":"insider"},{"id":8156906,"accession":"0001144204-19-027306","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-19-027306","line_url":"/filing/0001144204-19-027306#line-1","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Dexcel Pharma Technologies Ltd.; Dexxon Holdings Ltd.; Oren Dan","owner_display_name":"Dexcel Pharma Technologies Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares, $0.000037453 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5408.0,"shares_display":"5,408","price_per_share":6.7896,"price_display":"6.79","price_state":"stated","total_value":36718.1568,"total_display":"36,718.16","total_whole":"36,718","shares_owned_after":22709077.0,"shares_owned_after_display":"22,709,077","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-05-16","filed_date":"2019-05-20","scope":"insider"},{"id":7905593,"accession":"0001144204-19-014887","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-19-014887","line_url":"/filing/0001144204-19-014887#line-1","is_derivative":false,"issuer_cik":"0001636050","issuer_name":"Axovant Sciences Ltd.","issuer_ticker":"AXON","issuer_name_source":null,"issuer_url":"/issuer/0001636050","owner_cik":null,"owner_name":"Oren Dan; Dexxon Holdings Ltd.; Dexcel Pharma Technologies Ltd.","owner_display_name":"Oren Dan","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares, $0.00001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6666667.0,"shares_display":"6,666,667","price_per_share":1.5,"price_display":"1.50","price_state":"stated","total_value":10000000.5,"total_display":"10,000,000.50","total_whole":"10,000,001","shares_owned_after":105952381.0,"shares_owned_after_display":"105,952,381","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-03-18","filed_date":"2019-03-19","scope":"insider"},{"id":6717926,"accession":"0001144204-18-065508","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-18-065508","line_url":"/filing/0001144204-18-065508#line-1","is_derivative":false,"issuer_cik":"0001636050","issuer_name":"Axovant Sciences Ltd.","issuer_ticker":"AXON","issuer_name_source":null,"issuer_url":"/issuer/0001636050","owner_cik":null,"owner_name":"Dexxon Holdings Ltd.; Dexcel Pharma Technologies Ltd.; Oren Dan","owner_display_name":"Dexxon Holdings Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares, $0.00001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":10000000.0,"shares_display":"10,000,000","price_per_share":1.0,"price_display":"1.00","price_state":"stated","total_value":10000000.0,"total_display":"10,000,000.00","total_whole":"10,000,000","shares_owned_after":99285714.0,"shares_owned_after_display":"99,285,714","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-12-18","filed_date":"2018-12-20","scope":"insider"},{"id":6628727,"accession":"0001144204-18-052388","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-18-052388","line_url":"/filing/0001144204-18-052388#line-1","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Urovant Sciences Ltd.","issuer_ticker":"UROV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Oren Dan; Dexxon Holdings Ltd.; Dexcel Pharma Technologies Ltd.","owner_display_name":"Oren Dan","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares, $0.000037453 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2678571.0,"shares_display":"2,678,571","price_per_share":14.0,"price_display":"14.00","price_state":"stated","total_value":37499994.0,"total_display":"37,499,994.00","total_whole":"37,499,994","shares_owned_after":22703669.0,"shares_owned_after_display":"22,703,669","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-10-01","filed_date":"2018-10-03","scope":"insider"},{"id":6717653,"accession":"0001144204-18-033168","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-18-033168","line_url":"/filing/0001144204-18-033168#line-1","is_derivative":false,"issuer_cik":"0001636050","issuer_name":"Axovant Sciences Ltd.","issuer_ticker":"AXON","issuer_name_source":null,"issuer_url":"/issuer/0001636050","owner_cik":null,"owner_name":"Oren Dan; Dexxon Holdings Ltd.; Dexcel Pharma Technologies Ltd.","owner_display_name":"Oren Dan","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares, $0.00001 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":14285714.0,"shares_display":"14,285,714","price_per_share":1.75,"price_display":"1.75","price_state":"stated","total_value":24999999.5,"total_display":"24,999,999.50","total_whole":"25,000,000","shares_owned_after":89285714.0,"shares_owned_after_display":"89,285,714","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-06-05","filed_date":"2018-06-07","scope":"insider"},{"id":6228590,"accession":"0001144204-18-019287","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001144204-18-019287","line_url":"/filing/0001144204-18-019287#line-1","is_derivative":false,"issuer_cik":"0001636684","issuer_name":"Myovant Sciences Ltd.","issuer_ticker":"MYOV","issuer_name_source":null,"issuer_url":"/issuer/0001636684","owner_cik":null,"owner_name":"Dexcel Pharma Technologies Ltd.; Oren Dan; Dexxon Holdings Ltd.","owner_display_name":"Dexcel Pharma Technologies Ltd.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Shares, $0.000017727 par value per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1110015.0,"shares_display":"1,110,015","price_per_share":20.27,"price_display":"20.27","price_state":"stated","total_value":22500004.05,"total_display":"22,500,004.05","total_whole":"22,500,004","shares_owned_after":38341357.0,"shares_owned_after_display":"38,341,357","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-04-02","filed_date":"2018-04-04","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001635088","name":"Roivant Sciences Ltd.","url":"/issuer/0001635088","role":"Ten percent owner","n_filings":2,"first_seen":"2022-04-26","last_seen":"2022-11-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001006281","name":"Protalix BioTherapeutics, Inc.","url":"/issuer/0001006281","role":"Ten percent owner","n_filings":1,"first_seen":"2021-06-03","last_seen":"2021-06-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001638381","name":"Intec Pharma Ltd.","url":"/issuer/0001638381","role":"Ten percent owner","n_filings":1,"first_seen":"2020-02-04","last_seen":"2020-02-04"},{"type":"issuer","type_label":"ISSUER","cik":"0001740547","name":"Urovant Sciences Ltd.","url":"/issuer/0001740547","role":"Ten percent owner","n_filings":11,"first_seen":"2018-10-03","last_seen":"2019-06-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001679082","name":"Myovant Sciences Ltd.","url":"/issuer/0001679082","role":"Ten percent owner","n_filings":2,"first_seen":"2018-04-04","last_seen":"2019-06-06"},{"type":"issuer","type_label":"ISSUER","cik":"0001636050","name":"Axovant Sciences Ltd.","url":"/issuer/0001636050","role":"Ten percent owner","n_filings":3,"first_seen":"2018-06-07","last_seen":"2019-03-19"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001636701","retrieved_at":"2026-08-22T11:12:34+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}